To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
17 Current news of CeMMrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Solgate closes its first financing round with IST cube and private investors
Solgate GmbH, an Austrian early-stage biotech company, announces the completion of its first financing round from a group of venture and private investors. Solgate was incorporated in 2020 by a high-profile founding team and with intellectual property from the leading research institutions CeMM, ...
New therapeutic approach for the treatment of primary myelofibrosis
Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR). Scientists of the research group of Robert Kralovics, Adjunct Principal Investigator at the CeMM Research Center for Molecular ...
First highly scalable method developed to monitor protein levels and localizations in cells
CeMM researchers have developed a highly scalable method which allows for the study of hundreds of proteins in parallel in order to monitor the changes of their levels and localization in the cell. This novel strategy is a notable contribution, not only to drug development for future treatments ...
Exciting discovery could also explain why the body has maintained the “allergy module” throughout evolution
Researchers from CeMM Research Center of Molecular Medicine of the Austrian Academy of Sciences, the Medical University of Vienna and Stanford University School of Medicine, have found that a module of the immune system, which is best known for causing allergic reactions, plays a key role in ...
Discovery highlights a potential new target for the development of drugs to treat certain autoimmune diseases
How cells recognize pathogens and alert the immune system swiftly is a fundamental process of high importance for the survival of any species, including humans. A key role is ascribed to so-called adapters, that equal little molecular platforms inside cells where signals from pathogen detectors ...
Findings could open up potential therapeutic avenues to treat Type 1 diabetes
Researchers from Stefan Kubicek’s and Christoph Bock’s groups, at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, have developed a method to accurately assess the effect of specific drugs in isolated pancreatic tissue by using a refined single-cell ...
The first 21 SARS-CoV-2 genomes in Austria have now been completed and published within the scope of the “Mutational Dynamics of SARS-CoV-2” project recently launched by CeMM in close collaboration with the Medical University of Vienna. The project aims at sequencing 1,000 viral genomes obtained ...
Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences have developed a new methodology characterizing more precisely how drugs influence each other when combined during treatment. Their analysis of over 30k drug pairs applied to cell lines identified ...
Understanding resistance mechanisms to targeted protein degradation
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively. A recent study by researchers at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences reveals ...
More than one-fifth of all human cancers harbor mutations in one of the members of the BAF chromatin remodeling complex. Deep biochemical and epigenomic characterization of a cell line panel comprehensively representing all these mutations enabled researchers at the CeMM Research Center for ...